I've spent nearly all my working life as a journalist. I covered the rise and fall of the dot-com era in the second half of the 1990s, then switched to life sciences in the new millennium. I've written about the strategy, financing and scientific breakthroughs of biotech for The Deal, Elsevier's Start-Up, In Vivo and The Pink Sheet, and now Xconomy.
Is the J.P. Morgan CRISPR rollercoaster ride over? As rain fell heavily in San Francisco Monday, the first day of the massive healthcare conference, biotech stocks did, too. At least three... Read more »
Celgene (NASDAQ: CELG) has kicked off J.P. Morgan week—the annual healthcare investment gathering in San Francisco—with a blockbuster deal, acquiring privately held Impact Biomedicines for $1.1 billion upfront in cash.... Read more »
Welcome to the new year. What will it bring? Hopefully a lot less hatred, greed, stupidity, and angst than 2017. But we’re not holding our breath.
We emerged from the winter... Read more »
The first gene therapy approved in the United States will cost $850,000, its developer Spark Therapeutics (NASDAQ: ONCE) announced today. Spark hopes to reduce the sticker shock by offering refunds... Read more »
Next week, a big slice of the biomedical industry is gathering in San Francisco for the annual J.P. Morgan Healthcare Conference and other life sciences events that have emerged like sprouts... Read more »
In the penultimate week before the end-of-year recess, Congress raced to provide the drug industry—and the rest of corporate America—a massive tax cut, with breaks for investors, too. Racing to finish... Read more »
[Updated, 12/13/17, 1:50 p.m. ET. See below.] The annual American Society of Hematology meeting is nearly over. For now, we’ve chosen updates from three disease areas to highlight, plus... Read more »
[Corrected, 12/11/17, 1 p.m. ET. See below.] On Monday we posted the first part of our look at what should be some of 2018’s most important clinical data,... Read more »
In our roundup this week, Alzheimer’s disease is in the news, thanks to billionaire Bill Gates and his personal pledge of $100 million toward R&D. That could equal the amount one... Read more »
The researchers and doctors at Seattle Children’s are embarking upon a complicated quest, involving multiple clinical studies of cutting-edge CAR-T cell therapies, to help kids and young adults with an aggressive... Read more »
One of biotech’s richest private companies, Denali Therapeutics, has set its sights on an IPO to push ahead with treatments for Alzheimer’s and other confounding brain diseases.
When five patients with a difficult type of leukemia died last year in a clinical trial run by Juno Therapeutics, it was a big setback for the Seattle biotech and its... Read more »
The White House and the FDA turned the spotlight on the nation’s opioid crisis. Blockbuster drugs from Alexion and Tesaro gained expanded approvals, but bad earnings news from Celgene and Biogen... Read more »
As the quest to find treatments for Alzheimer’s disease keeps crashing against rocks, a group of researchers in the field want their peers to pay more attention to the part of... Read more »
For the second time in two months, remarkable recoveries from desperate cases of cancer have led to early approval of a cutting-edge therapy called CAR-T, which is made from a patient’s... Read more »
In advance of an anticipated Senate hearing on drug prices, President Donald Trump once again denounced drug companies as “getting away with murder.” The first time he did so, using the... Read more »
Cells within a single tumor can have a variety of genetic fingerprints. Understanding that variety is likely a key to fighting cancer in the near future.
A new biotech firm has... Read more »
In a year of tragedies across the U.S., natural or otherwise, it seemed this week was California’s turn. Fueled by high winds, low humidity, and ample dry vegetation, fires swept through... Read more »
June 14, 2018
© 2007-2018, Xconomy, Inc. Xconomy is a registered service mark of Xconomy, Inc. All rights reserved.